The University of Western Ontario

Other

Leland Stanford Junior University

Eli Lilly and Company

London Health Sciences Centre Research Inc.

Gregory A Dekaban

Arthur Brown

Kristine Kay Kikly

Ravi S Menon

Allan Barrett

Lynne Weaver

Jeffrey Holmes

J Kevin Shoemaker

Tanya Charyk Stewart

Charles A Rupar

Mark Daley

Steven Kok Hing Foung

Jacqueline Arp

Lisa Fischer

Robert Bartha

Douglas Dale Fraser

Timothy Doherty

Steven Kok Foung

Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as systemic inflammatory response following central nervous system trauma.

Anti-CD11D antibodies and uses thereof

A method of diagnosing central nervous system injuries such as acquired brain injury (ABI) and/or acquired spinal cord injury (ASI), including mild TBI (concussion or blast wave), mild ASI (contusion, stretch or partial cord transection), non-TBI brain injury and/or non-TSI spinal cord injury in a subject (animal or human). The method includes (a) obtaining a biological test sample from the subject, identifying metabolites in the subject's sample using metabolomics thereby obtaining a subject's metabolite matrix and generating a subject's profile using the patient's metabolite matrix; and (b) using multivariate statistical analysis and machine learning to compare the subject's profile with predetermined set of profiles of CNS injuries and a predetermined set of profiles of controls to determine if the subject has a CNS injury.

Metabolomics profiling of central nervous system injury

Isolated and purified envelope protein of HTLV-I is provided devoid of non-envelope protein of HTLV-I and having substantially the same conformation as the envelope protein in native HTLV-I. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Non-glycosylated and glycosylated forms of the protein are produced. Glycosylated forms are recognized by antibodies specific for the envelope protein of HTLV-I. Monoclonal antibodies are provided which are specific for the HTLV-I envelope protein and non-binding to HTLV-I envelope protein in denatured form. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV. The envelope protein is useful in diagnosis of infection by HTLV-I and HTLV-II.

Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor

Human T-cell lymphotropic virus type I envelope protein and human

Growing community of inventors

London, Canada

Gregory A Dekaban